# Neogen Corp: overview

NEOG · Nasdaq · CIK 711377 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/neog.md) · [Financials](/companies/neog/financials.md) · [Filings](/companies/neog/filings.md) · [Insiders](/companies/neog/insiders.md)

Latest reported revenue: [$222.8m](/filings/0001193125-26-416954.md) for Q1 FY2027, three months to 2026-08-31, from the 10-Q filed Oct 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-416954).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [231](/filings/0001193125-26-007682.md) | [221](/filings/0001193125-26-149599.md) | [226 d](/filings/0001193125-26-326092.md) | [209](/filings/0001193125-26-416954.md) | [225](/filings/0001193125-26-007682.md) | [211](/filings/0001193125-26-149599.md) | [225 d](/filings/0001193125-26-326092.md) | [223](/filings/0001193125-26-416954.md) |
| Gross margin | % | [49.0%](/filings/0001193125-26-007682.md) | [49.9%](/filings/0001193125-26-149599.md) | [41.2% d](/filings/0001193125-26-326092.md) | [45.4%](/filings/0001193125-26-416954.md) | [47.5%](/filings/0001193125-26-007682.md) | [46.9%](/filings/0001193125-26-149599.md) | [47.8% d](/filings/0001193125-26-326092.md) | [47.4%](/filings/0001193125-26-416954.md) |
| Operating margin | % | [(197.8%)](/filings/0001193125-26-007682.md) | [2.4%](/filings/0001193125-26-149599.md) | [(271.0%) d](/filings/0001193125-26-326092.md) | [(7.7%)](/filings/0001193125-26-416954.md) | [(2.4%)](/filings/0001193125-26-007682.md) | [(1.6%)](/filings/0001193125-26-149599.md) | [1.4% d](/filings/0001193125-26-326092.md) | [(0.8%)](/filings/0001193125-26-416954.md) |
| Net margin | % | [(197.3%)](/filings/0001193125-26-007682.md) | [(4.9%)](/filings/0001193125-26-149599.md) | [(271.5%) d](/filings/0001193125-26-326092.md) | [17.4%](/filings/0001193125-26-416954.md) | [(7.1%)](/filings/0001193125-26-007682.md) | [(8.0%)](/filings/0001193125-26-149599.md) | [(5.0%) d](/filings/0001193125-26-326092.md) | [(5.3%)](/filings/0001193125-26-416954.md) |
| Diluted EPS | $ per share | [(2.10)](/filings/0001193125-26-007682.md) | [(0.05)](/filings/0001193125-26-149599.md) | not reported | [0.17](/filings/0001193125-26-416954.md) | [(0.07)](/filings/0001193125-26-007682.md) | [(0.08)](/filings/0001193125-26-149599.md) | not reported | [(0.05)](/filings/0001193125-26-416954.md) |
| Free cash flow | $m | [23.1 d](/filings/0001193125-26-007682.md) | [(13.4) d](/filings/0001193125-26-149599.md) | [0.3 d](/filings/0001193125-26-326092.md) | [(13.2)](/filings/0001193125-26-416954.md) | [7.8 d](/filings/0001193125-26-007682.md) | [11.1 d](/filings/0001193125-26-149599.md) | [26.2 d](/filings/0001193125-26-326092.md) | [4.7](/filings/0001193125-26-416954.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [527](/filings/0000950170-24-087670.md) | [822](/filings/0000950170-25-100064.md) | [924](/filings/0001193125-26-326092.md) | [895](/filings/0001193125-26-326092.md) | [870](/filings/0001193125-26-326092.md) |
| Gross margin | % | [46.1%](/filings/0000950170-24-087670.md) | [49.4%](/filings/0000950170-25-100064.md) | [50.2%](/filings/0001193125-26-326092.md) | [47.1%](/filings/0001193125-26-326092.md) | [46.9%](/filings/0001193125-26-326092.md) |
| Operating margin | % | [11.1%](/filings/0000950170-24-087670.md) | [4.6%](/filings/0000950170-25-100064.md) | [6.3%](/filings/0001193125-26-326092.md) | [(118.6%)](/filings/0001193125-26-326092.md) | [(2.5%)](/filings/0001193125-26-326092.md) |
| Net margin | % | [9.2%](/filings/0000950170-24-087670.md) | [(2.8%)](/filings/0000950170-25-100064.md) | [(1.0%)](/filings/0001193125-26-326092.md) | [(122.1%)](/filings/0001193125-26-326092.md) | [(0.9%)](/filings/0001193125-26-326092.md) |
| Diluted EPS | $ per share | [0.45](/filings/0000950170-24-087670.md) | [(0.12)](/filings/0000950170-25-100064.md) | [(0.04)](/filings/0001193125-26-326092.md) | [(5.03)](/filings/0001193125-26-326092.md) | [(0.04)](/filings/0001193125-26-326092.md) |
| Free cash flow | $m | [43.6](/filings/0000950170-24-087670.md) | [(24.7)](/filings/0000950170-25-100064.md) | [(76.1)](/filings/0001193125-26-326092.md) | [(46.4)](/filings/0001193125-26-326092.md) | [31.9](/filings/0001193125-26-326092.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/neog/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $300.5m | 33,431,015 |  | Added +810,010 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $149.0m | 16,570,795 |  | Added +8,819,077 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $117.2m | 13,038,732 |  | Added +206,468 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $88.4m | 9,828,174 |  | Added +696,153 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $86.8m | 9,655,248 |  | Added +90,202 |
| [ING GROEP NV](/funds/1039765.md) | 2026-06-30 | $81.8m | 9,102,300 |  | Added +198,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $80.4m | 8,946,377 |  | Added +356,033 |
| [Gates Capital Management, Inc.](/funds/1312908.md) | 2026-06-30 | $78.6m | 8,742,274 |  | Added +2,483,625 |
| [Hudson Bay Capital Management LP](/funds/1393825.md) | 2026-06-30 | $58.4m | 6,500,000 |  | Reduced −180 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $52.4m | 5,832,899 |  | Added +271,286 |

## Recent filings

[All 1,367 filings](/companies/neog/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 09:16 ET | [8-K/A](/filings/0001193125-26-431208.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-431208 |
| 2026-10-07 | 16:02 ET | [10-Q](/filings/0001193125-26-416954.md) | Quarterly report, period 2026-08-31 | 0001193125-26-416954 |
| 2026-10-07 | 08:55 ET | [8-K](/filings/0001193125-26-416247.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-416247 |
| 2026-10-06 | 16:05 ET | [8-K](/filings/0001193125-26-415544.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-415544 |
| 2026-08-21 | 14:02 ET | [DEF 14A](/filings/0001193125-26-360742.md) | Proxy statement, period 2026-08-21 | 0001193125-26-360742 |
| 2026-08-07 | 16:02 ET | [8-K](/filings/0001193125-26-340216.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-340216 |
| 2026-07-30 | 16:04 ET | [10-K](/filings/0001193125-26-326092.md) | Annual report, period 2026-05-31 | 0001193125-26-326092 |
| 2026-07-30 | 07:01 ET | [8-K](/filings/0001193125-26-324860.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-324860 |
| 2026-04-20 | 06:59 ET | [8-K](/filings/0001193125-26-162667.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-162667 |
| 2026-04-09 | 16:03 ET | [10-Q](/filings/0001193125-26-149599.md) | Quarterly report, period 2026-02-28 | 0001193125-26-149599 |

## Latest annual report

[Form 10-K for the fiscal year ended May 31, 2026](/filings/0001193125-26-326092.md), filed Jul 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 711377
- Tickers: NEOG
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: MI
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 15:36 ET. No prices; not investment advice.